LAS VEGAS,NV--(Marketwired - September 26, 2013) - PharmaRoth Labs, Inc. (OTC Pink: ROTH) the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to announce that Dr. Jose Alberto Rojas Jimenez, a member of the company's Board of Advisors is presenting the results of a clinical trial he conducted on pre-Diabetic patients at the European Association for the Study of Diabetes (EASD) at their annual conference in Barcelona, Spain. The abstract of the trial will concurrently be included in the publication Diabetologia which will be distributed throughout the conference.
Mr.Luis Lopez, CEO of PharmaRoth, states: "The European conference is a very comprehensive gathering of the medical community of Europe focusing on Diabetes. The publication of the trial results in Diabetologia is a very prestigious honor for both Dr. Jimenez and PharmaRoth."
Mr. Lopez continues: "The trial was 12 weeks duration for pre-Diabetics. There were 98 patients involved using Sucanon®. The results were tremendously positive in the key metrics used to determine Type II Diabetes. Blood sugar stabilization and decrease of visceral belly fat were accomplished, without any side-effects. This small trial is another confirmation that Sucanon's® efficacy and safety are truly unique in the insulin sensitizer category with applicability extended to the pre-Diabetic segment as well."
Sucanon® is a dietary supplement containing natural ingredient. In certain ex-US countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies conducted ex-US have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico. Sucanon® will be marketed as a dietary supplement in the US.
For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.pharmaroth.com
About PharmaRoth Labs, Inc.
PharmaRoth Labs, Inc. (OTC Pink: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.